Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells

Stem Cells and Development

Volumn 24, Issue 1, 2015, Pages 93-103

  Rosado, Maria Manuela ^a   Bernardo, Maria Ester ^a   Scarsella, Marco ^a   Conforti, Antonella ^a   Giorda, Ezio ^a   Biagini, Simone ^a   Cascioli, Simona ^a   Rossi, Francesca ^a,b   Guzzo, Isabella ^a   Vivarelli, Marina ^a   Dello Strologo, Luca ^a   Emma, Francesco ^a   Locatelli, Franco ^a,c   Carsetti, Rita ^a,d  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d Department of Epidemiology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INTERACTION; CHILD; COCULTURE; CPG ISLAND; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; PERIPHERAL LYMPHOCYTE; PLASMA CELL; T LYMPHOCYTE; CELL COMMUNICATION; CELL PROLIFERATION; FEMALE; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; MALE; PRESCHOOL CHILD; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; ANTIBODY FORMATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; COCULTURE TECHNIQUES; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MESENCHYMAL STROMAL CELLS;

EID: 84919782445     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0155     Document Type: Article

References (49)

1. Horwitz EM, K Le Blanc, M Dominici, I Mueller, I Slaper-Cortenbach, Marini FC, Deans RJ, DS Krause and A Keating. (2005). Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. Cytotherapy 7:393-395.
2. Friedenstein AJ, UF Deriglasova, NN Kulagina, AF Panasuk, SF Rudakowa, EA Luria and IA Ruadkow. (1974). Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 2:83-92.
3. Fiorina P, M Jurewicz, A Augello, A Vergani, S Dada, S La Rosa, M Selig, J Godwin, K Law, et al. (2009). Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 183:993-1004.
4. Franquesa M, E Herrero, J Torras, E Ripoll, M Flaquer, M Goma, N Lloberas, I Anegon, JM Cruzado, JM Grinyo and I Herrero-Fresneda. (2012). Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 21:3125-3135.
5. Locatelli F, R Maccario and Frassoni F. (2007). Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders? Haematologica 92:872-877.
6. Nauta AJ and WE Fibbe. (2007). Immunomodulatory properties of mesenchymal stromal cells. Blood 110:3499-3506.
7. Uccelli A, V Pistoia and L Moretta. (2007). Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 28:219-226.
8. Franquesa M, MJ Hoogduijn, O Bestard and JM Grinyo. (2012). Immunomodulatory effect of mesenchymal stem cells on B cells. Front Immunol 3:212.
9. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, M Risso, F Gualandi, GL Mancardi, V Pistoia and A Uccelli. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372.
10. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24:386-398.
11. Traggiai E, S Volpi, F Schena, M Gattorno, F Ferlito, L Moretta and A Martini. (2008). Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients. Stem Cells 26:562-569.
12. Bernardo ME, D Pagliara and F Locatelli. (2012). Mesenchymal stromal cell therapy: a revolution in regenerative medicine? Bone Marrow Transplant 47:164-171.
13. Wise AF and SD Ricardo. (2012). Mesenchymal stem cells in kidney inflammation and repair. Nephrology (Carlton) 17:1-10.
14. Bernardo ME and WE Fibbe. (2012). Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Ann N Y Acad Sci 1266:107-117.
15. Schena F, C Gambini, A Gregorio, M Mosconi, D Reverberi, M Gattorno, S Casazza, A Uccelli, L Moretta, A Martini and E Traggiai. (2010). Interferon-gamma-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. Arthritis Rheum 62:2776-2786.
16. Zhou K, H Zhang, O Jin, X Feng, G Yao, Y Hou and L Sun. (2008). Transplantation of human bone marrow mesenchymal stem cell ameliorates the autoimmune pathogenesis in MRL/lpr mice. Cell Mol Immunol 5:417-424.
17. Capolunghi F, S Cascioli, E Giorda, MM Rosado, A Plebani, C Auriti, G Seganti, R Zuntini, S Ferrari, et al. (2008). CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol 180:800-808.
18. Aranburu A, S Ceccarelli, E Giorda, R Lasorella, G Ballatore and R Carsetti. (2010). TLR ligation triggers somatic hypermutation in transitional B cells inducing the generation of IgM memory B cells. J Immunol 185:7293-7301.
19. Capolunghi F, MM Rosado, S Cascioli, E Girolami, S Bordasco, M Vivarelli, B Ruggiero, E Cortis, A Insalaco, et al. (2010). Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. Rheumatology (Oxford) 49:2281-2289.
20. Vasilescu ER, EK Ho, AI Colovai, G Vlad, A Foca-Rodi, GS Markowitz, V D'Agati, MA Hardy, LE Ratner and N Suciu-Foca. (2006). Alloantibodies and the outcome of cadaver kidney allografts. Hum Immunol 67:597-604.
21. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822.
22. Di Ianni M, Del Papa B, De Ioanni M, L Moretti, E Bonifacio, D Cecchini, P Sportoletti, F Falzetti and A Tabilio. (2008). Mesenchymal cells recruit and regulate T regulatory cells. Exp Hematol 36:309-318.
23. Maccario R, M Podesta, A Moretta, A Cometa, P Comoli, D Montagna, L Daudt, A Ibatici, G Piaggio, et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90:516-525.
24. Leonardo SM, JL De Santis, LP Malherbe and SB Gauld. (2012). Cutting edge: in the absence of regulatory T cells, a unique Th cell population expands and leads to a loss of B cell anergy. J Immunol 188:5223-5226.
25. Choi J, ST Kim and J Craft. (2012). The pathogenesis of systemic lupus erythematosus-an update. Curr Opin Immunol 24:651-657.
26. Comoli P, F Ginevri, R Maccario, MA Avanzini, M Marconi, A Groff, A Cometa, M Cioni, L Porretti, et al. (2008). Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 23:1196-1202.
27. Nankivell BJ and SI Alexander. (2010). Rejection of the kidney allograft. N Engl J Med 363:1451-1462.
28. Carrion F, E Nova, P Luz, F Apablaza and F Figueroa. (2011). Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol Lett 135:10-16.
29. Wang Q, B Sun, D Wang, Y Ji, Q Kong, G Wang, J Wang, W Zhao, L Jin and H Li. (2008). Murine bone marrow mesenchymal stem cells cause mature dendritic cells to promote T-cell tolerance. Scand J Immunol 68:607-615.
30. Spaggiari GM, H Abdelrazik, F Becchetti and L Moretta. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 113:6576-6583.
31. Spaggiari GM, A Capobianco, H Abdelrazik, F Becchetti, MC Mingari and L Moretta. (2008). Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111:1327-1333.
32. Rasmusson I, K Le Blanc, B Sundberg and Ringden O. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand J Immunol 65:336-343.
33. Tabera S, JA Perez-Simon, M Diez-Campelo, LI Sanchez-Abarca, B Blanco, A Lopez, A Benito, E Ocio, FM Sanchez-Guijo, C Canizo and JF San Miguel. (2008). The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes. Haematologica 93:1301-1309.
34. Ghannam S, J Pene, Torcy-Moquet G, C Jorgensen and H Yssel. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185:302-312.
35. Kong QF, B Sun, SS Bai, DX Zhai, GY Wang, YM Liu, SJ Zhang, R Li, W Zhao, et al. (2009). Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGFbeta. J Neuroimmunol 207:83-91.
36. Bernasconi NL, E Traggiai and A Lanzavecchia. (2002). Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199-2202.
37. Zappia E, S Casazza, E Pedemonte, F Benvenuto, I Bonanni, E Gerdoni, D Giunti, A Ceravolo, F Cazzanti, et al. (2005). Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106:1755-1761.
38. Ko IK, Kim BG, A Awadallah, J Mikulan, P Lin, JJ Letterio and JE Dennis. (2010). Targeting improves MSC treatment of inflammatory bowel disease. Mol Ther 18: 1365-1372.
39. Ciccocioppo R, ME Bernardo, A Sgarella, R Maccario, MA Avanzini, C Ubezio, A Minelli, C Alvisi, A Vanoli, et al. (2011). Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 60:788-798.
40. Choi EW, IS Shin, SY Park, JH Park, JS Kim, EJ Yoon, SK Kang, JC Ra and SH Hong. (2012). Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum 64:243-253.
41. Youd M, C Blickarz, L Woodworth, T Touzjian, A Edling, J Tedstone, M Ruzek, R Tubo, J Kaplan and T Lodie. (2010). Allogeneic mesenchymal stem cells do not protect NZBxNZW F1 mice from developing lupus disease. Clin Exp Immunol 161:176-186.
42. Tyden G, H Genberg, J Tollemar, H Ekberg, Persson NH, G Tufveson, J Wadstrom, M Gabel and L Mjornstedt. (2009). A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation 87:1325-1329.
43. Walsh RC, RR Alloway, AL Girnita and ES Woodle. (2012). Proteasome inhibitor-based therapy for antibodymediated rejection. Kidney Int 81:1067-1074.
44. Mauri C and A Bosma. (2011). Immune regulatory function of B cells. Annu Rev Immunol 30:221-241.
45. Reichardt P, B Dornbach, S Rong, S Beissert, F Gueler, K Loser and M Gunzer. (2007). Naive B cells generate regulatory T cells in the presence of a mature immunologic synapse. Blood 110:1519-1529.
46. Kamar N, O Milioto, Puissant-Lubrano B, L Esposito, Pierre MC, Mohamed AO, L Lavayssiere, O Cointault, D Ribes, et al. (2010). Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10:89-98.
47. Casiraghi F, N Azzollini, M Todeschini, Cavinato RA, P Cassis, S Solini, C Rota, M Morigi, M Introna, et al. (2012). Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 12:2373-2383.
48. Seifert M, M Stolk, D Polenz and HD Volk. (2012). Detrimental effects of rat mesenchymal stromal cell pretreatment in a model of acute kidney rejection. Front Immunol 3:202.
49. Carrion F, E Nova, C Ruiz, F Diaz, C Inostroza, D Rojo, G Monckeberg and FE Figueroa. (2010). Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 19:317-322.